



ANDA 200823

Aurobindo Pharma USA, Inc.
U.S. Agent for: Aurobindo Pharma Limited
Attention: Blessy Johns
2400 Route 130 North
Dayton, NJ 08810

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated November 30, 2009, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15 mg (base)/500 mg and 15 mg (base)/850 mg.

Reference is also made to the tentative approval letter issued by this office on September 26, 2012, and your amendments dated October 4, and October 26, 2012; and January 17, 2013.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15 mg (base)/500 mg and 15 mg (base)/850 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Actoplus Met® Tablets, 15 mg (base)/500 mg and 15 mg (base)/850 mg, of Takeda Global Research Development Center Inc. (Takeda). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your ANDA.

The RLD upon which you have based your ANDA, Takeda's Actoplus Met® Tablets, is subject to periods of patent protection. The following patents and their expiration dates are currently listed in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") for this drug product:

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
5,965,584 (the '584 patent)	June 19, 2016
6,166,042 (the '042 patent)	June 19, 2016
6,166,043 (the '043 patent)	June 19, 2016
6,172,090 (the '090 patent)	June 19, 2016

With respect to each of these patents, your ANDA contains paragraph IV certifications under section 505(j)(2)(A)(vii)(IV) of the Act stating that each patent is invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15 mg (base)/500 mg and 15 mg (base)/850 mg, under this ANDA. You have notified the agency that Aurobindo Pharma Limited (Aurobindo) complied with the requirements of section 505(j)(2)(B) of the Act, and that litigation was initiated against Aurobindo for infringement of the '584, '043, and '090 patents within the statutory 45-day period in the United States District Court for the Southern District of New York [Takeda Pharmaceutical Co., Ltd, Takeda Pharmaceuticals North America, Inc., and Takeda Global Research and Development Center, Inc., vs. Aurobindo Pharma Ltd., and Aurobindo Pharma USA Inc., Civil Action No. 10 CIV 1339]. You have also notified the agency that the litigation has been terminated and you have entered into a license agreement with Takeda; therefore, under section 505(j)(5)(B)(iii) your ANDA is eligible for approval.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with

applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required).

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

{See appended electronic signature page}

Gregory P. Geba, M.D., M.P.H.
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT L WEST

02/13/2013

Deputy Director, Office of Generic Drugs, for
Gregory P. Geba, M.D., M.P.H.